ReviewExpert opinion on investigational drugs2013
Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.
Review in Expert opinion on investigational drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Carvedilol does not reduce cocaine use in methadone-maintained cocaine users.Journal of substance abuse treatment · 2017Trial
- The α-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals.Pharmacogenetics and genomics · 2016Trial
- Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.The international journal of neuropsychopharmacology · 2016Trial
- Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study.Drug and alcohol dependence · 2014Trial
- Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.Progress in neuro-psychopharmacology & biological psychiatry · 2014Trial
- Encoding of self-initiated actions in axon terminals of the mesocortical pathway.Neurophotonics · 2024Article
- Frontal white and gray matter abnormality in gambling disorder: A multimodal MRI study.Journal of behavioral addictions · 2024Article
- Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway.Psychopharmacology · 2022Article
- Potential Treat-to-Target Approach for Methamphetamine Use Disorder: A Pilot Study of Adenosine 2A Receptor Antagonist With Positron Emission Tomography.Frontiers in pharmacology · 2022Article
- Drug addiction: from bench to bedside.Translational psychiatry · 2021Review
- Effects of an Adenosine AFrontiers in neuroscience · 2021Article
- COMT val158met genotype alters the effects of methamphetamine dependence on dopamine and dopamine-related executive function: preliminary findings.Psychiatry research · 2020Article
- Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.Psychopharmacology · 2020Article
- Dopamine and addiction: what have we learned from 40 years of research.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- Selective inhibition of MAddiction biology · 2018Article
- Social Status in Monkeys: Effects of Social Confrontation on Brain Function and Cocaine Self-Administration.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Sex differences in reinstatement of cocaine-seeking with combination treatments of progesterone and atomoxetine.Pharmacology, biochemistry, and behavior · 2016Article
- The effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats.Behavioural brain research · 2016Article
- Effects of prior cocaine self-administration on cognitive performance in female cynomolgus monkeys.Psychopharmacology · 2015Article
Corrections and comments
- Erratum issuedDe La Garza, Richard [corrected to De La Garza, Richard 2nd]
Authors and funding
6 authors.
Funding
Abstract
introductionIllicit substance-use is a substantial public health concern, contributing over $150 billion in costs annually to Americans. A complex disease, a substance-use disorder affects neural circuits involved in reinforcement, motivation, learning and memory, and inhibitory control. AREAS COVERED: The modulatory influence of dopamine in mesocorticolimbic circuits contributes to encoding the primary reinforcing effects of substances and numerous studies suggest that aberrant signaling within these circuits contributes to the development of a substance-use disorder in some individuals. Decades of research focused on the clinical development of medications that directly target dopamine receptors has led to recent studies of agonist-like dopaminergic treatments for stimulant-use disorders and, more recently, cannabis-use disorder. Human studies evaluating the efficacy of dopaminergic agonist-like medications to reduce reinforcing effects and substance-use provide some insight into the design of future pharmacotherapy trials. A search of PubMed using specific brain regions, medications, and/or the terms 'dopamine', 'cognition', 'reinforcement', 'cocaine', 'methamphetamine', 'amphetamine', 'cannabis', 'treatment/pharmacotherapy', 'addiction/abuse/dependence' identified articles relevant to this review. EXPERT OPINION: Conceptualization of substance-use disorders and their treatment continues to evolve. Current efforts increasingly focus on a strategy fostering combination pharmacotherapies that target multiple neurotransmitter systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.